0000950170-23-053381.txt : 20231013 0000950170-23-053381.hdr.sgml : 20231013 20231013201841 ACCESSION NUMBER: 0000950170-23-053381 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20231011 FILED AS OF DATE: 20231013 DATE AS OF CHANGE: 20231013 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Buell Jennifer CENTRAL INDEX KEY: 0001711184 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-40908 FILM NUMBER: 231326060 BUSINESS ADDRESS: BUSINESS PHONE: 781-674-4400 MAIL ADDRESS: STREET 1: 3 FORBES ROAD CITY: LEXINGTON STATE: MA ZIP: 02421 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: MiNK Therapeutics, Inc. CENTRAL INDEX KEY: 0001840229 STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836] IRS NUMBER: 000000000 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 149 FIFTH AVENUE STREET 2: SUITE 500 CITY: NEW YORK STATE: NY ZIP: 10010 BUSINESS PHONE: 212-994-8250 MAIL ADDRESS: STREET 1: 149 FIFTH AVENUE STREET 2: SUITE 500 CITY: NEW YORK STATE: NY ZIP: 10010 FORMER COMPANY: FORMER CONFORMED NAME: AgenTus Therapeutics, Inc. DATE OF NAME CHANGE: 20210112 4 1 ownership.xml 4 X0508 4 2023-10-11 0001840229 MiNK Therapeutics, Inc. INKT 0001711184 Buell Jennifer 149 FIFTH AVENUE, SUITE 500 NEW YORK NY 10010 true true false false Chief Executive Officer false Common Stock 2023-10-11 4 J false 695750 D 232165 D Restricted Stock Units 2023-10-11 4 A false 695750 0.00 D Common Stock 695750 0 D Dr. Jennifer Buell was awarded Restricted Stock Units ("RSUs") which corresponded to 695,750 shares of MiNK Therapeutics, Inc. ("Company") common stock ("Common Stock"). These RSUs, tied to the Company's Initial Public Offering ("IPO"), vested on September 27, 2023. Dr. Buell previously reported on Form 4s the receipt of such shares of Common Stock (the "RSU Shares") and subsequent sales of shares of Common Stock to cover Federal, state and local tax withholding requirements. However, the Company and Dr. Buell agreed that it is in the best interests of the Company and its stockholders for Dr. Buell to forfeit that award in lieu of a new award that will vest over a period of five years (see Explanation of Responses #2). Therefore Dr. Buell is returning the RSU Shares to the Company. Dr Buell has thus made the Company whole for the forfeited award by returning 695,750 shares of Company Common Stock to the Company on October 11, 2023 for no consideration. On October 11, 2023, in alignment with the Company's 2021 Equity Incentive Plan, Dr. Buell received a grant of 695,750 RSUs. This new grant serves as a replacement for the RSUs initially awarded during the Company's IPO, which Dr. Buell forfeited and returned to the Company on October 11, 2023. These newly granted RSUs will vest over a five-year period, with one-third of the restricted stock units vesting on each of the third, fourth and fifth anniversaries of the grant date. By: /s/ Christine Klaskin, Attorney-in-Fact for Jennifer S. Buell 2023-10-13